Table 2: Results table for studies with adequate data for meta-analysis.b

Author
Year
Country
HCA formulationRandomised/ AnalysedAge in yrsHCA DosageTreatment DurationBaseline weight indices for HCA/placebo groupsMean change in weight indices for HCA/placebo groupsAdverse events (AE)Control for lifestyle factors

Hayamizu et al. 2001 Japan [24]Tablets 40/40
(HCA)

(PLA)
1 g daily8 weeksBW:
/
BMI:
/
BW:

BMI:
No serious AE reportedDietary control

Heymsfield et al. 1998 U.S.A. [25]Capsules 135/135
(HCA)

(PLA)
1.5 g daily12 weeksBW:
/
BMI:
/
BW:
Headache, URTI & GI symptomsHigh fibre diet, stable physical activity levels

Kovacs et al. 2001 Netherlands [26]Unspecified 21/21
for both HCA&placebo groups
1.5 g daily2 weeksMean BW:

Mean BMI:
BW:
/
Not reportedNo restriction on food intake; 1 glass of alcohol maximum daily

*§Kovacs et al. 2001 Netherlands [27] Unspecified 11/11
for both HCA&placebo groups
1.5 g daily2 weeksMean BW:

Mean BMI:
BW:
/
Not reportedNo restriction on food intake; 1 glass of alcohol maximum daily

Mattes and Bormann 2000 U.S.A. [5]Caplets167/89
(HCA)

(PLA)
1.2 g daily12 weeksBW:
/
BMI:
/
BW:
/
Not reportedDietary control, exercise encouraged, but no formal regimen prescribed

§Preuss et al. 2004 India [29]Unspecified 60/53Range: 21–502.8 g daily8 weeksBW:
/
BMI:
/
BW:
/
BMI:
Gas, stomach burn, headache, skin rashDietary control, walking exercise programme

§Preuss et al. 2004 India [6]Unspecified 30/29Range: 21–502.8 g daily8 weeksBW:
/
BMI:
/
BW:
/
BMI:
No serious AE reportedDietary control, walking exercise programme

Ramos et al. 1995 Mexico [30]Capsules40/ 35
(HCA)

(PLA)
1.5 g daily8 weeksBMI:
/
BW:
/
Nausea, headacheDietary control

Roongpisu-thipong et al. 2007 Thailand [2]Sachets 50/42
(HCA)

(PLA)
Unclear8 weeksBW:
/
BMI:
/
BW:

BMI:
Not reportedDietary control

Abbreviations: HCA: Hydroxycitric acid; PLA: Placebo; BW: Body Weight; BMI: Body Mass Index.
bUnless otherwise specified, values for age, baseline weight and mean change in weight indices have been reported as means with standard deviations.
*Studies included as crossover design, otherwise all included trials had parallel-study design.
§Studies with 3 intervention groups.